Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 122.97% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-11
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 122.97%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 111.82%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 108.50%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-03-31 was 102.70%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2015 was 102.23%, a 0.00% change from fiscal 2014.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2014 was 102.23%, a 0.00% change from fiscal 2013.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2013 was 102.23%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 122.97% 10-Q · filed 2026-08-11 | ||||
| 2026-03-31 | 122.97% 10-Q · filed 2026-05-12 | ||||
| 2024-03-31 | 111.82% 10-Q · filed 2025-05-12 | ||||
| 2022-06-30 | 108.50% 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 108.50% 10-Q · filed 2023-05-11 | ||||
| 2020-03-31 | 102.70% 10-Q · filed 2021-05-14 | ||||
| 2018-06-30 | 100.00% 10-Q · filed 2018-08-14 | ||||
| 2018-03-31 | 99.90% 10-Q · filed 2019-05-15 | ||||
| 2017-09-30 | 90.40% 10-Q · filed 2018-11-14 | ||||
| 2017-06-30 | 90.40% 10-Q · filed 2018-08-14 | ||||
| 2016-06-30 | 89.10% 10-Q · filed 2016-08-15 | ||||
| 2015-12-31 | 102.23% 10-K · filed 2016-03-30 | ||||
| 2014-12-31 | 102.23% 10-K · filed 2015-03-12 | ||||
| 2014-03-31 | 100.72% 10-Q · filed 2014-05-08 | ||||
| 2013-12-31 | 102.23% 10-K · filed 2014-03-13 | ||||
| 2013-09-30 | 102.23% 10-Q · filed 2013-11-12 | ||||
| 2013-06-30 | 102.23% 10-Q · filed 2013-08-08 | ||||
| 2013-03-31 | 83.41% 10-Q · filed 2014-05-08 | 102.23% 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |